Kimberly-Clark Agrees to Buy Tylenol Maker Kenvue for $48.7 Billion -

Kleenex and Huggies now share a roof with Tylenol and Listerine after Kimberly-Clark completed its acquisition of Kenvue while the Tylenol maker was fighting a Texas lawsuit over acetaminophen and autism claims.

Kimberly-Clark completed its acquisition of Kenvue on November 2, 2026, one year after announcing the cash-and-stock deal valuing the Tylenol parent at an enterprise value of about $48.7 billion. Kenvue shareholders received $3.50 in cash plus 0.14625 shares of Kimberly-Clark stock for every share they held, terms valued at $21.01 a share when the agreement was announced. Former Kimberly-Clark shareholders own roughly 54% of the combined company and former Kenvue holders own the rest.

Put the two product lists side by side and you get a strange kind of monopoly on American bathroom cabinets and diaper bags alike. Huggies, Pull-Ups, Kleenex, Scott and Cottonelle sit on one side. Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno and Zyrtec sit on the other. Together they form a company with about $32 billion in annual revenue, $7 billion in adjusted EBITDA, and ten billion-dollar brands sold in more than 175 countries, according to the deal filings.

Kenvue has had a rough two years to get here. Johnson & Johnson spun the company off in 2023. The stock has struggled since, dragged down by a wave of litigation and, more recently, a very public fight over Tylenol’s safety. In October, President Trump told pregnant women to stop taking Tylenol, pointing to an unproven link between acetaminophen and autism. Weeks later, Texas Attorney General Ken Paxton sued both J&J and Kenvue, alleging the companies hid the drug’s risks and that J&J structured the 2023 spinoff specifically to wall off liability. Kenvue has called the autism claims misinformation, maintaining that acetaminophen remains the safest pain reliever option for pregnant women. The American College of Obstetricians and Gynecologists called Trump’s comments irresponsible.

None of that stopped Kimberly-Clark.

If anything, buying a bruised but still-dominant brand portfolio at a defined price looks like the kind of bet activist-adjacent boards make when they think the controversy is noise around a durable asset, not a sign the asset is broken.

Financing the deal took some engineering. Kimberly-Clark funded the cash portion using cash on hand, debt financing, and proceeds from selling a 51% stake in its International Family Care and Professional business, according to the closing filings. That’s a meaningful piece of Kimberly-Clark’s own footprint going out the door to fund the Kenvue purchase, and it signals the company was willing to narrow its own international exposure to win scale in North American consumer health.

The projected payoff is $1.9 billion in cost savings plus another $500 million in extra revenue, offset by $300 million of reinvestment, all expected within four years of closing. Every merger makes that kind of multi-year promise. Every merger is also judged against it years later, when the maths inevitably runs behind schedule.

Shareholders of both companies approved the transaction in January 2026, and Kimberly-Clark completed it after obtaining the required regulatory clearances. The combination puts a substantial collection of diaper, tissue and over-the-counter medicine brands under one roof. Big, boring, cash-generating consumer brands are still doing serious dealmaking well outside the data center.

Those risks haven’t gone away. Kimberly-Clark closed the acquisition with Kenvue still facing litigation and political scrutiny over Tylenol, and its closing disclosures identify legal proceedings, government investigations, and indemnification obligations involving Johnson & Johnson among the risks surrounding the acquisition and integration.

Also read: Revolut Shows Cheap Unlimited Tokens, Not Smarter AI, Is What Speeds Up Coding • Mistral Is Racing OpenAI and xAI on a Fraction of Their GPUs • Looking for an Eventbrite Alternative? How Small Organizers Are Selling Tickets Without Juggling Five Tools